Israel Englander Viking Therapeutics, Inc. Call Options Transaction History

Millennium Management LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$49.84 - $70.47 $3.07 Million - $4.34 Million	-61,600 Reduced 86.03%	10,000 $633,000
Q2 2024 Aug 14, 2024	BUY	$47.39 - $80.2 $2.91 Million - $4.92 Million	61,400 Added 601.96%	71,600 $3.8 Million
Q1 2024 May 15, 2024	BUY	$17.4 - $94.5 $177,480 - $963,900	10,200 New	10,200 $836,000
Q2 2023 Aug 14, 2023	SELL	$14.84 - $24.79 $3.15 Million - $5.26 Million	-212,300 Reduced 63.32%	123,000 $1.99 Million
Q1 2023 May 15, 2023	SELL	$8.08 - $17.33 $900,112 - $1.93 Million	-111,400 Reduced 24.94%	335,300 $5.58 Million
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $1.22 Million - $4.2 Million	446,700 New	446,700 $4.2 Million

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.95B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.